Partnership expands Bespak’s intranasal dry powder capabilities

New long‑term results reinforce efficacy across AD and PN

New option offers acute treatment for adults with migraine

Final analysis shows durable outcomes in MF and SS

First long‑acting therapy targeting root cause of ATTR‑CM

Collaboration to expand personalised cancer immunotherapy

Company expands pipeline into car‑t and genetic medicine

Early findings support phase 2 plans for 2027

Call aims to support research preventing deadly newborn infections

Guidance supports use when standard therapies fail